Item 7.01. Regulation FD Disclosure.
On March 20, 2017, Aevi Genomic Medicine, Inc. (the “Company”) issued a press release announcing topline results from the SAGA trial of AEVI001 (oral nonstimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD. The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The Company hosted a conference call and live audio webcast on Monday, March 20, 2017 to discuss the results from the SAGA trial of AEVI001. The Company referred to the slide presentation, attached as Exhibit 99.2 and incorporated by reference herein, on the conference call. The slide presentation, together with an archive of the webcast, will also be available for 30 days after the date of the conference call in the Investor section of the Company’s website at www.aevigenomics.com.
The information in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are furnished herewith:
Exhibit No. Description
Aevi Genomic Medicine, Inc. Press Release dated March 20, 2017 (furnished pursuant to Item 7.01).
Slide Presentation dated March 20, 2017 (furnished pursuant to Item 7.01).